Home Novo Nordisk A/S (NVO) Receives Sell Rating from Zacks Investment Research
 

Keywords :   


Novo Nordisk A/S (NVO) Receives Sell Rating from Zacks Investment Research

2016-01-17 15:45:50| Biotech - Topix.net

's stock had its "sell" rating reissued by Zacks Investment Research in a research report issued to clients and investors on Sunday, MarketBeat.Com reports. According to Zacks, "Novo Nordisk's third-quarter 2015 results were strong with revenues increased on the back of robust performance from Victoza and Levemir as well as significant contributions from Tresiba and Saxenda.

Tags: research rating sell investment

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
28.11SCR
28.1146
28.11BOSS OD-2 TURBO Over Drive
28.11/ Pulling the Plug
28.11
28.1110
28.112.5 120
28.11MSV-R
More »